Seminoma is the most common testicular germ cell tumor worldwide and mainly occurs in 15-35-year-old young men. Early studies have indicated that testicular nuclear receptor 4 (TR4) first cloned from testis is involved in the invasion and metastasis of several human tumors; however, little attention is paid to the function of TR4 in seminoma. Our immunohistochemical (IHC) staining results showed that patients with advanced stage tumors tended to have higher expression of TR4.
Seminoma is the most common testicular germ cell tumor worldwide and mainly occurs in 15-35-year-old young men. Early studies have indicated that testicular nuclear receptor 4 (TR4) first cloned from testis is involved in the invasion and metastasis of several human tumors; however, little attention is paid to the function of TR4 in seminoma. Our immunohistochemical (IHC) staining results showed that patients with advanced stage tumors tended to have higher expression of TR4.
Importantly, there was a significant association between elevated TR4 expression and reduced overall survival in seminoma patients. In vitro MTS, western blot and transwell assays, after manipulating TR4 expression in Tcam-2 cells, revealed that TR4 induced epithelial-to-mesenchymal transition (EMT) and promoted Tcam-2 cell proliferation and invasion. Mechanism dissection demonstrated that AKT3, a critical component in the signaling pathway, played a crucial role in mediating TR4-promoted Tcam-2 cell proliferation and invasion. We further revealed that TR4 modulated AKT3 at the transcriptional level via chromatin immunoprecipitation and luciferase assays. Meanwhile, addition of the AKT3 siRNA blocked the function of TR4. Overall, these findings first elucidate that TR4 is a novel prognostic marker and plays a critical role in the metastatic capacity of Tcam-2 cells by EMT regulation and, consequently, targeting TR4-AKT3 pathway may serve as a potential therapeutic approach for seminoma.
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| INTRODUCTION
Testicular cancer is the most common cancer diagnosed for men from 15 to 35 years old, with seminoma accounting for 40%-60% of cases.
1,2 Although the 5-year survival rate for testicular cancer confined to the testis is approximately 99.2%, the rate drops to 73.1%
for those who suffer from distant metastasis. [3] [4] [5] However, the precise molecular pathogenesis and the progression mechanisms of seminoma remain uncertain. 6, 7 To date, no reliable biological parameter is available to differentiate metastasized stages from non-metastasized seminoma. 8 The testicular nuclear receptor 4 (TR4), an alias for the nuclear receptor subfamily 2 group C member 2 (NR2C2) gene, is a transcriptional regulator that belongs to the nuclear receptor superfamily, which can regulate gene expression at transcription level by binding to the AGGTCA direct repeat separated by a variable length of Yuanlei Chen, Jieyang Lu and Liqun Xia are contributed equally to the present study.
DNA. 9 In vivo studies of TR4 knockout mice (TR4 À/À ) suggested that TR4 might play important roles in modulating the physiological process, including glucose, lipid and bone metabolism, fertility and aging. 10 Recently, the impacts of TR4 on development and therapy resistance of various cancers have also been investigated. The results revealed that TR4 could promote progression of prostate cancer, renal cell carcinoma and non-small cell lung cancer as well as boost radio/chemo-therapy resistance of prostate cancer. 11, 12 The influence of TR4 on seminoma progression, however, remains unclear.
AKT is known to be the central protein of signaling pathway involved in cell survival, tumor metastasis, drug resistance, metabolism and radiation resistance. 13 There are three different AKT isoforms, AKT1, AKT2 and AKT3. Although former studies have focused on the role of Akt1 and Akt2 in cancer progression, little is known about AKT3.
In the current work, we aimed to explore the contribution of TR4 in seminoma progression and found that TR4 might be able to function through activation of the AKT3 expression to drive the EMT phenotype and enhance the seminoma cell proliferation and invasion. Overall, these results suggested a novel biological parameter to distinguish metastasized stages and a potential therapeutic target for seminoma. were cultured in the same condition.
| MATERIALS AND METHODS

| Cell culture
| Antibodies and reagents
Anti-TR4 antibody (ab109301) was purchased from Abcam. Anti-GAPDH (6c5) antibody (sc-202525) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-AKT1 (ab81283), Anti-AKT2 (ab38513) and Anti-AKT3 (ab152157) antibodies were purchased from Abcam. Anti-snail (ab53519), Anti-E-cadherin (ab1416), Anti-N-cadherin (ab18203) and Anti-vimentin (ab8978) antibodies were purchased from Abcam.
| Plasmids
To construct the pWPI-TR4 plasmid, full-length TR4 cDNA was ligated into the PmeI site of the pWPI vector. 
| MTS assay
The Tcam-2 cells were plated on 96-well plates at a density of 5 9 10 3 per well. We added MTS (CellTiter 96-cell proliferation assay kit; Promega, Madison, WI, USA) into each well after 0, 1, 2, 3 and 4 days in culture. We read the absorbance at 490 nm to determine the cells' viability in each well.
| Colony formation assay
Approximately 1000 transfected Tcam-2 cells were replated into 6-well dishes. Two weeks later, visible colonies were fixed and stained with crystal violet, and the colony formation ratio was calculated
with the following formula: (visible colony numbers/original number of cells) 9 100%. Data are presented as the mean AE SD and experiments were performed in triplicate.
| Western blotting
Cells were harvested and washed twice with cold PBS, then resuspended and lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 ng/mL PMSF, 0.03% aprotinin, 1 l mol L
À1
sodium orthovanadate) at 4°C for 30 minutes. Lysates were centrifuged for 20 minutes at 14 000 g and supernatants were stored at À80°C as whole cell extracts. Total protein concentrations were determined by bicinchoninic acid protein assay kit. Proteins (20 lg)
were separated on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. After blocking membranes with 5% BSA, they were incubated with appropriate dilutions of specific primary antibodies. Corresponding HRP-conjugated secondary antibodies were used against each primary antibody. Proteins were detected using the chemiluminescent detection reagents.
| siRNA transfection
We planted Tcam-2 cells at a density of 8 Nuclei were counterstained with DAPI for 10 minutes at room temperature. The cells were then observed under a TCS-SP5
confocal laser scanning microscope (LEICA, Wetzlar, Germany).
| Immunohistochemical staining
Tissues were fixed in 10% (v/v) formaldehyde in PBS, embedded in paraffin and cut into 4-mm sections and used for IHC staining with human TR4 antibodies. To enhance antigen exposure, the slides were treated with 1X EDTA at 98°C for 10 minutes for antigen retrieval. The slides were incubated with endogenous peroxidase blocking solution to inhibit endogenous peroxidase and were then incubated with the primary antibody at room temperature for 60 minutes. After rinsing with Tris-buffered saline, the slides were incubated for 45 minutes with biotin-conjugated secondary antibody, washed, and then incubated with enzyme conjugate HRP-streptavidin. Freshly prepared DAB (Zymed, South San Francisco, CA, USA) was used as a substrate to detect HRP. Finally, slides were counterstained with hematoxylin and mounted with aqueous mounting media. German immunoreactive score (IRS) was applied to testify the protein levels. First, the IRS assigns subscores for the percentage of immunoreactive cells (0-4) and immunoreactive intensity (0-3), then multiplies them to yield the IRS score, which ranged from 0 to 12.
The percent positivity was scored as "0" (<1%), "1" (1%-10%), "2"
(11%-50%), "3" (51%-80%) and "4" (>80%). The staining intensity was scored as "0" (negative), "1" (weak), "2" (moderate) and "3" 
| Cell migration and invasion assays
Briefly, cells were seeded in top chambers of the transwell plates (BD Biosciences, San Jose, CA, USA) in 5% serum media with membrane inserts coated either with or without Matrigel (8%) for invasion and migration tests, respectively. Bottom chambers were filled with DMEM medium with 10% FBS. After 12-18 hours (for migration) or 36-48 hours (for invasion) incubation, cells that migrated/invaded to the lower surface of the membrane were fixed and stained, and the cell numbers in six random fields were counted under the light microscope.
| ChIP assay
Tcam-2 cells (1. Table 1 . Moreover, TR4 positive frequency was also higher in those patients with higher clinical stage ( Figure 1B) . Consistently, the mRNA expression of TR4 is positively related with clinical tumor stage in The Cancer Genome Atlas (TCGA) database ( Figure 1C ). In addition, we found that seminoma patients with higher expression of TR4 tended to have a poorer outcome. As is shown in Figure 1D , increased TR4 expression was associated with shorter overall survival. In summary, these findings suggested that TR4 expression might be positively correlated with seminoma progression and poor survival.
| TR4 enhanced the proliferation ability in seminoma cells
Because TR4 expression was increased in advanced clinical tumor samples, we first tested whether TR4 had an influence on the prolif- 
| DISCUSSION
The alarming decline in male reproductive health over the past century has been associated with reduced semen quality, rising rates of developmental abnormalities and increased prevalence of testicular germ cell tumors. 14 In the United States, 1 out of every 250 men will be diagnosed with testicular cancer in their lifetime 15, 16 and for unknown reasons this rate has been increasing over the past decades in the United States and other western countries. 17 Seminoma is the most common type of testicular germ cell tumor (TGCT); however, the detailed mechanisms of its pathogenesis and metastatic factor 4E (eIF4E) in human solid tumors and hematological malignancies. 13, 20 Different AKT isoforms, encoded by three separate genes, are believed to have different functions depending on the cell types and cancer types. 21, 22 In our research, we found that TR4 can specifically modulate AKT3 but not AKT1 and AKT2.
A growing number of publications have been highlighting the importance of AKT3 expression in various cancers. [23] [24] [25] Several studies have documented that elevated AKT3 was involved in the regulation of proliferation and invasion in thyroid cancer, malignant melanoma cells and hepatocellular carcinoma. [26] [27] [28] As an oncogene, the activation of Akt3 contributes significantly to increased invasion abilities through upregulation of MYC proto-oncogene (C-myc) and vascular endothelial growth factor precursor (VEGF), which are known to trigger tumorigenesis and angiogenesis, respectively. The protein expression of p27, p53, p21 and caspase-3 could be inhibited by Akt3 overexpression, whereas the expression of B-cell lymphoma-2 (Bcl2), Cyclin D1 and X-linked inhibitor of apoptosis (XIAP)
were elevated, elucidating that Akt3 could inhibit the apoptosis and promote the proliferation abilities of tumor cells. 29, 30 However, interestingly, the role of AKT3 in tumor progression may be controversial.
Recently a study indicated that AKT3 delayed tumor progression in glioblastoma, 31 showing that a gene may play different roles in different cancers due to a distinct tumor microenvironment. Here, in mechanism dissection studies, we screened several genes that were associated with seminoma progression and the results showed that 
